文献速递胸部肿瘤

FGTI-2734通过抑制ERK再激活克服KRAS G12C肺癌对索托拉西布的耐药

FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2024-11-26

KRAS G12C靶向治疗如索托拉西布总体缓解率和无进展生存期有限,耐药机制涉及ERK适应性再激活,需野生型HRAS和NRAS膜定位。本研究表明双法尼基转移酶和香叶基香叶基转移酶-1抑制剂FGTI-2734可抑制野生型RAS膜定位及索托拉西布诱导的ERK反馈再激活,克服索托拉西布适应性耐药。FGTI-2734与索托拉西布联用协同抑制KRAS G12C肺癌细胞活力并诱导凋亡,在体内增强索托拉西布抗肿瘤活性,使KRAS G12C肺癌患者来源异种移植瘤及高度耐药细胞异种移植瘤显著退缩,并抑制索托拉西布诱导的ERK再激活。

要点

  • FGTI-2734抑制野生型RAS膜定位及索托拉西布诱导的ERK反馈再激活。
  • FGTI-2734与索托拉西布联用协同抑制KRAS G12C肺癌细胞活力并诱导凋亡。
  • FGTI-2734增强索托拉西布体内抗肿瘤活性,使KRAS G12C肺癌PDX及耐药细胞异种移植瘤显著退缩。

核心结论

  • 研究结果为克服索托拉西布耐药并可能改善KRAS G12C肺癌治疗结局提供了基础。

研究设计与样本

  • 本研究为体外和体内实验研究,使用KRAS G12C肺癌细胞、患者来源异种移植瘤(PDX)及高度索托拉西布耐药KRAS G12C人肺癌细胞异种移植瘤,并给小鼠使用FGTI-2734和索托拉西布。

主要发现

  • FGTI-2734抑制野生型RAS膜定位和索托拉西布诱导的ERK反馈再激活,并克服索托拉西布适应性耐药。
  • FGTI-2734与索托拉西布联用在抑制KRAS G12C肺癌细胞活力及诱导凋亡方面具有协同作用,包括对索托拉西布高度耐药的细胞。
  • FGTI-2734增强索托拉西布体内抗肿瘤活性,使KRAS G12C肺癌患者PDX及多个高度索托拉西布耐药KRAS G12C人肺癌细胞异种移植瘤显著退缩。
  • 小鼠中FGTI-2734治疗抑制KRAS G12C PDX中索托拉西布诱导的ERK再激活。
  • FGTI-2734与索托拉西布联用在小鼠中显著更有效抑制索托拉西布耐药人KRAS G12C肺癌异种移植瘤和NSCLC PDX的体内P-ERK水平。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: KRAS G12C targeted therapies, such as sotorasib, represent a major breakthrough, but overall response rates and progression-free survival for patients with KRAS G12C lung cancer are modest due to the emergence of resistance mechanisms involving adaptive reactivation of ERK, which requires wild-type HRAS and NRAS membrane localization. METHODS AND RESULTS: Here, we demonstrate that the dual farnesyltransferase and geranylgeranyltransferase-1 inhibitor FGTI-2734 inhibits wild-type RAS membrane localization and sotorasib-induced ERK feedback reactivation, and overcomes sotorasib adaptive resistance. The combination of FGTI-2734 and sotorasib is synergistic at inhibiting the viability and inducing apoptosis of KRAS G12C lung cancer cells, including those highly resistant to sotorasib. FGTI-2734 enhances sotorasib's anti-tumor activity in vivo leading to significant tumor regression of a patient-derived xenograft (PDX) from a patient with KRAS G12C lung cancer and several xenografts from highly sotorasib-resistant KRAS G12C human lung cancer cells. Importantly, treatment of mice with FGTI-2734 inhibited sotorasib-induced ERK reactivation in KRAS G12C PDX, and treatment of mice with the combination of FGTI-2734 and sotorasib was also significantly more effective at suppressing in vivo the levels of P-ERK in sotorasib-resistant human KRAS G12C lung cancer xenografts and the NSCLC PDX. CONCLUSION: Our findings provide a foundation for overcoming sotorasib resistance and potentially improving the treatment outcomes of KRAS G12C lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kazi A, Vasiyani H, Ghosh D, et al. FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer. J Thorac Oncol. 2024. PMID: 39603412. doi:10.1016/j.jtho.2024.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。